Literature DB >> 15334021

The construction of a new evaluative GERD questionnaire - methods and state of the art.

David Armstrong1, Hubert Mönnikes, Karna Dev Bardhan, Vincenzo Stanghellini.   

Abstract

Gastroesophageal reflux disease (GERD) is one of the most prevalent diseases worldwide, and it is becoming increasingly important to monitor the effect of various interventions on GERD symptoms. There can be rapid temporal changes in the severity and frequency of patients' symptoms as well as their health status and well-being, all of which could, theoretically, be monitored using diaries or questionnaires. However, current GERD monitoring instruments are not appropriate because they do not assess symptoms daily, they are not sufficiently responsive to short-term changes in health status or they are not adequately validated. To address these problems, the conceptual and psychometric requirements for a GERD symptom assessment questionnaire were identified. A dimension-based scale was designed to reduce the number of symptoms monitored on a daily basis, and the validation process was defined to produce parallel long and short forms of a scale for patients' self-assessment of their GERD symptom response to therapy. These basic principles which underlie the successful development of a new, self-assessed symptomatic reflux questionnaire (ReQuest(TM)) are also applicable to the development of validated questionnaires for daily symptom self-assessment in other disease areas. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2004        PMID: 15334021     DOI: 10.1159/000080465

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  9 in total

Review 1.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

2.  Natural history of heartburn: a 10-year population-based study.

Authors:  Linda Bjork Olafsdottir; Hallgrimur Gudjonsson; Heidur Hrund Jonsdottir; Bjarni Thjodleifsson
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

3.  Gastroesophageal reflux disease and physical activity.

Authors:  Pawel Jozkow; Dorota Wasko-Czopnik; Marek Medras; Leszek Paradowski
Journal:  Sports Med       Date:  2006       Impact factor: 11.136

4.  Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease.

Authors:  Hubert Mönnikes; Robert C Heading; Holger Schmitt; Hubert Doerfler
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 5.  The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.

Authors:  Alan B R Thomson
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.

Authors:  José María Remes-Troche; Sergio Sobrino-Cossío; Julio César Soto-Pérez; Oscar Teramoto-Matsubara; Miguel Morales-Arámbula; Antonio Orozco-Gamiz; José Luis Tamayo de la Cuesta; Gualberto Mateos
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 2.859

7.  Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group.

Authors:  I M Modlin; R H Hunt; P Malfertheiner; P Moayyedi; E M Quigley; G N J Tytgat; J Tack; R C Heading; G Holtman; S F Moss
Journal:  Digestion       Date:  2009-06-17       Impact factor: 3.216

8.  Patient or physician - who is able to evaluate gastroesophageal reflux disease symptoms better?

Authors:  Anita Gasiorowska
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

9.  Impact of PPIs on patient focused symptomatology in GERD.

Authors:  Abr Thomson
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.